Trieu Vuong

CIK 00015870743 companiesSAN DIEGO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001587074

Recent Transactions

50 trades

Award
Oncotelic Therapeutics, Inc.$OTLC
Series A Convertible Preferred Stock
2025-11-17+4,065→ 4,065 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2025-07-10$0.01/sh+104,000→ 93,293,560 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2025-07-09$0.01/sh+1→ 93,293,561 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2025-07-08$0.01/sh+94,736→ 93,388,297 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2025-01-31$0.03/sh+63,775→ 93,189,560 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2025-01-30$0.03/sh+100,003→ 93,125,785 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2025-01-29$0.03/sh+183,066→ 93,025,782 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2024-11-22$0.03/sh+298,499→ 92,842,716 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2024-08-23$0.02/sh+500,000→ 92,544,217 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2023-06-29$0.02/sh+425,000→ 92,044,217 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2023-06-28$0.03/sh+75,000→ 91,619,217 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2023-06-16$0.03/sh+100,000→ 91,544,217 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2023-06-14$0.03/sh+400,000→ 91,444,217 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2023-05-26$0.03/sh+126,888→ 91,044,217 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2023-05-02$0.04/sh+100,000→ 90,917,329 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2022-12-06$0.05/sh+120,000→ 90,558,021 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2022-11-22$0.08/sh+70,000→ 90,438,021 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2022-09-26$0.07/sh+20,000→ 90,368,021 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2022-08-25$0.08/sh+80,000→ 90,348,021 total
Award
Oncotelic Therapeutics, Inc.$OTLC
Stock Options
2021-09-03+225,000→ 225,000 total
Award
Oncotelic Therapeutics, Inc.$OTLC
Stock Options
2021-07-08+513,953→ 513,953 total
Award
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2021-07-08+259,302→ 90,527,323 total
Conversion
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2021-03-31+74,455,719→ 90,268,021 total
Conversion
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2021-03-31+5,672,025→ 6,872,529 total
Conversion
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2021-03-31+13,849,161→ 16,780,384 total
Conversion
Oncotelic Therapeutics, Inc.$OTLC
Series A Convertible Preferred Stock
2021-03-31−13,849→ 0 total
Conversion
Oncotelic Therapeutics, Inc.$OTLC
Series A Convertible Preferred Stock
2021-03-31−74,456→ 0 total
Conversion
Oncotelic Therapeutics, Inc.$OTLC
Series A Convertible Preferred Stock
2021-03-31−5,672→ 0 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2020-11-19$0.19/sh+50,500→ 15,812,308 total
Purchase
Oncotelic Therapeutics, Inc.$OTLC
Common Stock
2020-03-26$0.12/sh+3,000→ 15,761,808 total
Disposition to Issuer
Adhera Therapeutics, Inc.$ATRX
Common Stock
2018-10-01$0.50/sh−500,000→ 612,716 total
Purchase
Adhera Therapeutics, Inc.$ATRX
Warrants to Purchase Common Stock
2018-04-16+2,564,465→ 2,564,465 total
Award
Adhera Therapeutics, Inc.$ATRX
Series E Convertible Preferred Stock
2018-04-16$5000.00/sh+2.25→ 2.25 total
Conversion
Adhera Therapeutics, Inc.$ATRX
Warrants to Purchase Common Stock
2018-04-16+859,725→ 859,725 total
Conversion
Adhera Therapeutics, Inc.$ATRX
Warrants to Purchase Common Stock
2018-04-16+142,500→ 142,500 total
Conversion
Adhera Therapeutics, Inc.$ATRX
Warrants to Purchase Common Stock
2018-04-16+258,825→ 258,825 total
Conversion
Adhera Therapeutics, Inc.$ATRX
Series E Convertible Preferred Stock
2018-04-16$5000.00/sh+34.51→ 34.51 total
Conversion
Adhera Therapeutics, Inc.$ATRX
5% Convertible Promissory Note
2018-04-16
Conversion
Adhera Therapeutics, Inc.$ATRX
Series E Convertible Preferred Stock
2018-04-16$5000.00/sh+114.63→ 114.63 total
Conversion
Adhera Therapeutics, Inc.$ATRX
5% Demand Line of Credit
2018-04-16
Award
Adhera Therapeutics, Inc.$ATRX
Warrants to Purchase Common Stock
2018-04-16+16,875→ 16,875 total
Conversion
Adhera Therapeutics, Inc.$ATRX
5% Demand Line of Credit
2018-04-16
Conversion
Adhera Therapeutics, Inc.$ATRX
Series E Convertible Preferred Stock
2018-04-16$5000.00/sh+19→ 19 total
Purchase
Adhera Therapeutics, Inc.$ATRX
Series E Convertible Preferred Stock
2018-04-16$5000.00/sh+162.59→ 162.59 total
Award
Adhera Therapeutics, Inc.$ATRX
Options to purchase common stock
2018-01-03+3,800→ 3,800 total
Award
Adhera Therapeutics, Inc.$ATRX
5% Convertible Promissory Note
2017-06-30$165634.00/sh→ 473,240 total
Purchase
Adhera Therapeutics, Inc.$ATRX
Common Stock
2017-06-09$0.39/sh+10,000→ 11,127,141 total
Purchase
Adhera Therapeutics, Inc.$ATRX
Common Stock
2017-06-08$0.39/sh+20,000→ 11,117,141 total
Purchase
Adhera Therapeutics, Inc.$ATRX
Common Stock
2017-06-07$0.38/sh+2,500→ 11,097,141 total
Purchase
Adhera Therapeutics, Inc.$ATRX
Common Stock
2017-02-06$0.29/sh+862,068→ 862,068 total

Companies

Recent Filings

Address

C/O SORRENTO THERAPEUTICS, INC. 6042 CORNERSTONE CT. WEST, SUITE B

SAN DIEGO, CA, 92121

View on SEC.gov